KRAS and colorectal carcinoma: Similarly, mutant KRAS is present in 30–40% of colorectal cancers (CRC) and almost 25% of patients with Non-Small Cell Lung Cancer (NSCLC), where it correlates with poor prognosis and high risk of recurrence (Stephen et al., 2014).